Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Protagonist Therapeutics Inc. : Announces Closing of $132.2 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

06/21/2021 | 10:41am EDT

Protagonist Therapeutics, Inc. (Nasdaq:PTGX), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 3,503,311 shares of its common stock, including 456,953 shares sold pursuant to the underwriters' exercise in full of their 'green shoe' option to purchase additional shares, at a price to the public of $37.75 per share.

Aggregate gross proceeds to Protagonist from the offering were approximately $132.2 million, before deducting underwriting discounts and commissions and offering expenses.

J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler acted as joint book-running managers for the offering. JMP Securities LLC and H.C. Wainwright & Co., LLC acted as co-lead managers for the offering.

A shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC) on December 10, 2020. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and is available on the SEC's website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to the offering may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 866-803-9204, or by email at prospectus-eq_fi@jpmchase.com; Jefferies LLC (Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022; telephone: 877-821-7388; email: Prospectus_Department@Jefferies.com); or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at prospectus@psc.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contact:

Tel: (212) 600-1902

Email:joshua@argotpartners.com

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about PROTAGONIST THERAPEUTICS, INC.
09/20Top Midday Decliners
MT
09/20PROTAGONIST THERAPEUTICS : Reports FDA Clinical Hold on Rusfertide Clinical Deve..
AQ
09/20PROTAGONIST THERAPEUTICS : SVB Leerink Adjusts Protagonist Therapeutics' Price T..
MT
09/20PROTAGONIST THERAPEUTICS : HC Wainwright Adjusts Protagonist Therapeutics' Price..
MT
09/20PROTAGONIST THERAPEUTICS : JPMorgan Downgrades Protagonist Therapeutics to Neutr..
MT
09/20PROTAGONIST THERAPEUTICS' : Clinical Studies of Rusfertide Placed on Hold by FDA..
MT
09/17PROTAGONIST THERAPEUTICS : Reports FDA Clinical Hold on Rusfertide Clinical Deve..
PU
09/17PROTAGONIST THERAPEUTICS, INC : Other Events, Financial Statements and Exhibits ..
AQ
09/17NASDAQ 100 : Top Midday Decliners
MT
09/17PROTAGONIST THERAPEUTICS : Northland Capital Downgrades Protagonist Therapeutics..
MT
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 14,2 M - -
Net income 2021 -117 M - -
Net cash 2021 250 M - -
P/E ratio 2021 -5,06x
Yield 2021 -
Capitalization 616 M 616 M -
EV / Sales 2021 25,7x
EV / Sales 2022 9,57x
Nbr of Employees 101
Free-Float 98,6%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 12,95 $
Average target price 49,43 $
Spread / Average Target 282%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Donald A. Kalkofen Chief Financial Officer
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.-35.76%616
MODERNA, INC.305.22%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.41.30%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-9.18%28 420